Avalo Therapeutics, Inc.

Avalo Therapeutics achieved a positive Phase‑2 study outcome for therapies targeting immune‑mediated inflammatory diseases and also secured new capital to continue development. The company remains clinically focused and currently generates no revenue. Bank of America recommends buying the stock with a price target of $35, citing the clinical results and the financial refresh. » Plus sur finanzen.net

At Avalo Therapeutics’ annual general meeting all seven directors were elected through 2027, the revised 2016 employee stock purchase plan was approved, and Ernst & Young LLP was confirmed as the independent auditor for fiscal 2026. About 85% of outstanding shares were represented or voted. The company also set a $375 million share placement with an offering price of $17.75 per common share and raised roughly $40 million after announcing positive Phase II LOTUS data. Analysts adjusted price targets in response, while some maintained buy ratings. » Plus sur de.investing.com

The randomized, double‑blind phase 2 LOTUS study (253 adults) showed that Abdakibart achieved significantly higher HiSCR75 rates at week 16 (150 mg 42.2%, p=0.018; 300 mg 42.9%, p=0.015) versus placebo (25.6%); the combined dose analysis was also significant. Key secondary endpoints also improved, efficacy was independent of prior biologic treatment, and the safety profile was comparable to placebo with mostly mild to moderate adverse events. Avalo plans a regulatory‑enabling phase 3 program and will present full results at a congress. Investors reacted positively: the stock rose and market capitalization is about USD 426.9 million, while three analysts raised estimates and set price targets of USD 24 to USD 52. » Plus sur de.investing.com